Prostalund Ab Stock Beta
| PLUN Stock | SEK 5.70 0.50 9.62% |
ProstaLund AB fundamentals help investors to digest information that contributes to ProstaLund's financial success or failures. It also enables traders to predict the movement of ProstaLund Stock. The fundamental analysis module provides a way to measure ProstaLund's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ProstaLund stock.
ProstaLund |
ProstaLund AB Company Beta Analysis
ProstaLund's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current ProstaLund Beta | 0.84 |
Most of ProstaLund's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ProstaLund AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, ProstaLund AB has a Beta of 0.8359. This is 2.8% lower than that of the Healthcare sector and significantly higher than that of the Medical Care Facilities industry. The beta for all Sweden stocks is notably lower than that of the firm.
ProstaLund Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ProstaLund's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ProstaLund could also be used in its relative valuation, which is a method of valuing ProstaLund by comparing valuation metrics of similar companies.ProstaLund is currently under evaluation in beta category among its peers.
As returns on the market increase, ProstaLund's returns are expected to increase less than the market. However, during the bear market, the loss of holding ProstaLund is expected to be smaller as well.
ProstaLund Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.61) % | |||
| Operating Margin | (0.59) % | |||
| Current Valuation | 215.81 M | |||
| Shares Outstanding | 57.19 M | |||
| Shares Owned By Insiders | 50.77 % | |||
| Shares Owned By Institutions | 1.93 % | |||
| Price To Book | 5.09 X | |||
| Price To Sales | 13.54 X | |||
| Revenue | 17.07 M | |||
| Gross Profit | 14.68 M | |||
| EBITDA | (7.54 M) | |||
| Net Income | (7.88 M) | |||
| Cash And Equivalents | 19.11 M | |||
| Cash Per Share | 2.98 X | |||
| Current Ratio | 6.11 X | |||
| Book Value Per Share | 0.79 X | |||
| Cash Flow From Operations | (5.8 M) | |||
| Earnings Per Share | (0.17) X | |||
| Beta | 0.84 | |||
| Market Capitalization | 248.19 M | |||
| Total Asset | 43.48 M | |||
| Retained Earnings | 19 M | |||
| Current Asset | 27 M | |||
| Current Liabilities | 4 M | |||
| Net Asset | 43.48 M |
About ProstaLund Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProstaLund AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProstaLund using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProstaLund AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ProstaLund Stock Analysis
When running ProstaLund's price analysis, check to measure ProstaLund's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProstaLund is operating at the current time. Most of ProstaLund's value examination focuses on studying past and present price action to predict the probability of ProstaLund's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProstaLund's price. Additionally, you may evaluate how the addition of ProstaLund to your portfolios can decrease your overall portfolio volatility.